Your browser doesn't support javascript.
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
Giudice, Valentina; Pagliano, Pasquale; Vatrella, Alessandro; Masullo, Alfonso; Poto, Sergio; Polverino, Benedetto Maria; Gammaldi, Renato; Maglio, Angelantonio; Sellitto, Carmine; Vitale, Carolina; Serio, Bianca; Cuffa, Bianca; Borrelli, Anna; Vecchione, Carmine; Filippelli, Amelia; Selleri, Carmine.
  • Giudice V; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" University of Salerno, Baronissi, Italy.
  • Pagliano P; Clinical Pharmacology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Vatrella A; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" University of Salerno, Baronissi, Italy.
  • Masullo A; Infectious Disease Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Poto S; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" University of Salerno, Baronissi, Italy.
  • Polverino BM; Intensive Care Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Gammaldi R; Infectious Disease Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Maglio A; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" University of Salerno, Baronissi, Italy.
  • Sellitto C; Intensive Care Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Vitale C; Respiratory Disease Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Serio B; Respiratory Endoscopy Unit, Hospital "Giovanni Da Procida", University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Cuffa B; Intensive Care Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Borrelli A; Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" University of Salerno, Baronissi, Italy.
  • Vecchione C; Clinical Pharmacology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Filippelli A; Intensive Care Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Selleri C; Hematology and Transplant Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Front Pharmacol ; 11: 857, 2020.
Article in English | MEDLINE | ID: covidwho-615557
ABSTRACT
To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of three weeks, or with the best available therapy (N = 10). Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and decrease in circulating D-dimer levels compared to the best available therapy group. Our results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.00857

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.00857